Journal
DIABETES OBESITY & METABOLISM
Volume 15, Issue 2, Pages 189-191Publisher
WILEY
DOI: 10.1111/j.1463-1326.2012.01691.x
Keywords
glycaemic control; metformin; pharmacogenetics; type 2 diabetes
Categories
Funding
- Ministry of Education, Science, Research and Sport of Slovak Republic [VEGA 1/0112/11, VEGA 1/0340/12]
- Slovakian Agency for Research and Development [APVV-0134-11]
Ask authors/readers for more resources
Pharmacogenetic studies revealed that variants in genes related to the pharmacokinetics of metformin were associated with glucose-lowering effect of metformin. The aim of this study was to investigate possible associations of the variants in genes encoding organic cationic transporterssolute carrier family 22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1 (SLC47A1) with response to metformin in type 2 diabetes. One hundred forty-eight drug-naive patients with type 2 diabetes were included in the study. Genotyping for SLC22A1 rs622342, SLC22A2 rs316019 and SLC47A1 rs2289669 variants was performed using real-time PCR with subsequent melting-curve analysis. SLC47A1 rs2289669 genotype was significantly associated with the reduction in haemoglobin A1c (HbA1c) after 6?months. Twenty percentage of patients with diabetes that are homozygous for A-allele of SLC47A1 had twofold reduction in HbA1c in comparison with the patients carrying G-allele (GG?+?GA: 0.55 +/- 0.09% vs. AA: 1.10 +/- 0.18%, p?=?0.018). In conclusion, the results of this study might have in future practical implication in personalised treatment of patients with type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available